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Variability in activity of CYP2C9, which is involved in the metabolism of approximately
15% of current therapeutic drugs, is an important contributor to interindividual differences
in drug response. To evaluate the functional alternations of CYP2C9∗2, CYP2C9∗3,
CYP2C9∗8, CYP2C9∗11 and CYP2C9∗31, identified in our previous study in Chinese
Han population, allelic variants as well as the wild-type CYP2C9 were transiently
expressed in COS-7 cells. Kinetic parameters (Km, Vmax, and Clint) for S-warfarin 7-
hydroxylation by these recombinant CYP2C9s were determined. Relative to CYP2C9.1,
recombinant CYP2C9.3 and CYP2C9.11 exhibited significantly higher Km values, and
all allelic variants showed significantly decreased Vmax and Clint values. Among all
allelic variants, catalytic activity of CYP2C9.3 and CYP2C9.11 reduced the most (8.2%
and 9.8% of Clint ratio, respectively; P < 0.001). These findings should be useful for
predicting the phenotype profiles of CYP2C9 in Chinese Han population, comparing the
functional results of these alleles accurately, and finally optimizing pharmacotherapy of
drug treatment.
Keywords: cytochrome P450, genetic polymorphisms, pharmacokinetics, in vitro models, HPLC (high-
performance/pressure liquid chromatography), S-warfarin, Chinese Han
INTRODUCTION
Human cytochrome P450 2C9 (CYP2C9) is one of the most important members of the
cytochrome P450 superfamily, accounting for ∼20% of hepatic total CYP content and
involved in the metabolism of approximately 15% of current therapeutic drugs, including
antibiotic, anticancer, antidiabetic, antiepileptic, antihypertensive, cannabinol, non-steroidal anti-
inflammatory, anticoagulant, and anti-hyperlipidemic drugs (Zhou et al., 2010). in addition, lots
of endogenous compounds, such as progesterone, testosterone and arachidonic acid, are also
metabolized by CYP2C9 (Rifkind et al., 1995; Yamazaki and Shimada, 1997). Alternation of
CYP2C9 activity is an important contributor to the interindividual differences in drug response. For
example, patients carrying CYP2C9∗2 or CYP2C9∗3, both of which will lead to reduced enzymatic
activity, were reported to have higher risk for adverse drug responses, when they were treated with
warfarin or S-acenocoumarol (Higashi et al., 2002; Malhi et al., 2004; Visser et al., 2004).
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To date, 67 variants of CYP2C9 (∗1A through to
∗60) located in the coding region have been identified
(http://www.cypalleles.ki.se/cyp2c9.htm). Besides, different
ethnic populations often show considerable differences in
frequencies of CYP2C9 alleles. For example, CYP2C9∗2 and
CYP2C9∗3 were reported to have relatively higher frequencies
in Caucasians than in African-Americans, while CYP2C9∗5
was found almost exclusively in African-Americans (Zhou
et al., 2010). Consequently, functional characterization of
different CYP2C9 variants, especially variants identified in
the same ethnic population, is of great importance for the
optimal pharmacotherapy of drug treatment, particularly for the
appropriate dosing of drugs with a narrow therapeutic index
such as warfarin.
In our previous study, we identified five CYP2C9 alleles
in four geographically different Chinese Han populations,
namely CYP2C9∗2, CYP2C9∗3, CYP2C9∗8, CYP2C9∗11, and
CYP2C9∗31 (Xiong et al., 2011). Even though there have
been many reports concerning functional characterization of
these CYP2C9 allelic variants in vitro, some of these studies
reported discordant kinetic parameters of the same CYP2C9
variant toward the same substrate. For example, Kaminsky
et al. (1993) reported that yeast-expressed CYP2C9.2 exhibited
increased catalytic activity toward S-warfarin hydroxylation,
while Rettie et al. (1994, 1999) reported that recombinant
CYP2C9.2 expressed in insect cells or HepG2 cells showed
decreased activity toward S-warfarin metabolism. Besides, most
of these studies were performed using recombinant CYP2C9s
expressed in E.coli, yeast or insect cells (Hiratsuka, 2012), which
were less relevant with human CYP2C9 variant proteins than
mammalian cell-expressed CYP2C9s. What is more, most of
previous studies using the mammalian cell-based expression
system only focused on parts of these CYP2C9 alleles (Hiratsuka,
2012). It is difficult to assess activity alternation of these CYP2C9s
with data obtained under different experiment conditions. To
our knowledge, only Niinuma et al. (2014) have studied all of
these alleles with the mammalian cell based expression system.
However, they obtained only parts of accurate kinetic parameters
of all alleles, which is not enough to compare the activity
alternation comprehensively.
To get a systematical and accurate assessment on the
functional alternations of these CYP2C9 alleles, which is
useful for predicting the CYP2C9 phenotype profile and
optimizing drug administration in Chinese Han population,
we characterized their enzymatic activity in vitro using S-
warfarin as a representative substrate. Recombinant CYP2C9s
were prepared by transfecting COS-7 cells with cDNAs of
CYP2C9∗1, CYP2C9∗2, CYP2C9∗3, CYP2C9∗8, CYP2C9∗11, and
CYP2C9∗31. Enzymatic activity of them toward S-warfarin 7-
hydroxylation were examined by HPLC (High Performance
Liquid Chromatography).
MATERIALS AND METHODS
Construction of Expression Plasmids
CYP2C9∗1 cDNA in pCMV6-XL5 plasmid (Origene, Rockville,
MD, USA) was released by digestion with EcoR I and Xba I
(Thermo Scientific, Beijing, China), and then subcloned into
pcDNA3.1 (±) vector (Invitrogen, Carlsbad, CA, USA). Site-
directed mutagenesis to introduce the 430C>T (CYP2C9∗2),
449G>A (CYP2C9∗8), 980T>C (CYP2C9∗31), 1003C>T
(CYP2C9∗11), and 1075A>C (CYP2C9∗3) transitions was
performed using pcDNA3.1 (±) carrying human CYP2C9∗1
cDNA as the template for polymerase chain reaction
amplification by Pyrobest DNA polymerase (TaKaRa, Dalian,
China). The specific base transition was introduced into the
amplification products by a pair of completely complementary
primers containing the substituted base (Supplemental Table
1). After incubation with Dpn I (Thermo Scientific) to digest
the template and purification, these vectors were transformed
into E. coli Top 10 (Tiangen, Beijing, China), and then purified
with NucleoBond Xtra plasmid purification Kit (MACHEREY-
NAGEL, Germany). Clones carrying the desired mutants were
identified by direct DNA sequencing. DNA concentration
and quality were evaluated with Nano Drop 2000 UV-Vis
Spectrophotometer (Thermo, Wilmington, DE, USA).
TRANSFECTION OF COS-7 CELLS AND
PREPARATION OF MICROSOMES
COS-7 cells were seeded on 10-cm culture dishes in Dulbecco’s
modified Eagle’s medium (DMEM; ATCC, VA, USA) containing
10% Fetal bovine serum (FBS; PAA, Piscataway, NJ, USA),
100 U/mL penicillin (Invitrogen), 100U/mL streptomycin
(Invitrogen), and 0.01mg/mL Plasmocin (Invitrogen). When
cells were∼90% confluent, vectors carrying desired cDNAs were
transfected into the COS-7 cells with TransFectin Lipid Reagent
(Bio-Rad, Hercules, CA, USA) according to the manufacturer’s
guidelines. The optimal transfection efficiency and cell viability
were obtained with 24µg DNA/dish and 50µL TransFectin
Lipid Reagent. 48 h after transfection, cells were scrapped
from the culture dishes, washed twice with 100mM potassium
phosphate buffer (pH 7.4), and then resuspended in 20mM
potassium phosphate buffer (pH 7.4), containing 0.2mM EDTA,
1mM dithiothreitol, and 20% glycerol (Guo et al., 2005).
After sonication, the homogenate was centrifuged at 9000 g,
4◦C for 20min. Subsequently, the resulting supernatant was
centrifuged at 105,000 g, 4◦C for 60min. The microsomal pellet
was resuspended in 250mM sucrose and stored at−80◦C.
DETERMINATION OF COS-7 EXPRESSED
CYP2C9 VARIANT PROTEINS
Total protein concentration of COS-7 cell expressed microsomes
was measured by Bradford method (Bradford, 1976) using the
Bio-Rad protein assay (Bio-Rad) according to the manufacturer’s
guidelines. Microsomal CYP2C9 apoprotein levels were
determined by immunoblotting, with a serial of dilution of
baculovirus-expressed CYP2C9 (BD, San Jose, CA, USA) as
the standard. Recombinant proteins were separated on 10%
sodium dodecyl sulfate-polyacrylamide gels and transferred to
polyvinylidene difluoride membranes (Millipore Corporation,
Billerica, MA). After incubation with the rabbit-produced
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anti-CYP2C9 antibody (Sigma-Aldrich, St. Louis, MO, USA), the
primary antibody, at 4◦C for 24 h, the membrane was incubated
with the HRP-conjugated anti-rabbit IgG (Sigma-Aldrich) for
2 h at room temperature. Bands were visualized by incubating
the membrane with the chemiluminescent peroxidase substrate
(Sigma-Aldrich), and analyzed with Image J software (National
Institutes of Health, Bethesda, MD, USA). Experiments were
conducted in triplicate independently.
IN VITRO S-WARFARIN
7-HYDROXYLATION AND HPLC ANALYSIS
For the preparation of the (S)-warfarin stock solution [1mM (S)-
warfarin in 5mMKOH], 0.0145mmol (S)-warfarin was dissolved
in 70 ul 1MKOH and further diluted with water to a final volume
of 14.5ml. Each incubation mixture of (S)-warfarin contained
a final concentration of 0.5mM KOH; the final pH of the
incubation mixtures was 7.4 (Hemeryck et al., 1999).
S-warfarin (2–100µM; Sigma-Aldrich) was incubated at 37◦C
with microsomes(5–20 pmol) expressed from COS-7 cells and
a NADPH-generating system (consisting of 1mM NADP+,
10mM glucose-6-phosphate, 5mM MgCl2 and 2U/mL glucose-
6-phosphate dehydrogenase; Sigma-Aldrich) in 0.1M potassium
phosphate buffer (pH 7.4). The total volume of every incubation
was 250µL. Reactions were initiated by adding the NADPH-
generating system, after the pre-incubation (37◦C, 5min).
Then after 2-h incubation with gentle shaking, reactions were
quenched with 100µL cold acetonitrile, containing 0.2µg
7-Ethoxycoumarin (Sigma-Aldrich) as the internal standard.
Subsequently, the mixture was centrifuged at 12,000 g, 4◦C
for 20min. Resulting supernatant was then passed through
a syringe nylon filter (13mm, 0.45µm; Dikma Technologies,
Lake Forest, CA, USA), and 50µL of the filtrate was injected
for HPLC analysis. Every reaction was performed in triplicate
independently.
HPLC analysis was performed using the Agilent 1260 HPLC
system. 7-Hydroxywarfarin (Sigma-Aldrich) and the internal
standard 7-ethoxycoumarin were separated on an Agilent
ZORBAX SB-C18 column at ambient temperature. The mobile
phase, a mixture of acetonitrile and 0.5% phosphoric acid (38:62,
V/V), was pumped at a flow rate of 1mL/min. The lower limit
of 7-hydroxywarfarin quantification was 0.20 nM. Fluorescence
detection was performed at an excitation wavelength of 320 nm
and an emission wavelength of 415 nm (Lang and Bocker, 1995).
Under these conditions, retention time of 7-hydroxywarfarin
and 7-ethoxycoumarin was 7.3 and 8.7min, respectively. A 7-
point standard curve was used to quantify the amount of 7-
hydroxywarfarin in samples.
DATA ANALYSIS
Brands of Western Blot were analyzed using Image J software.
The standard curve of baculovirus-expressed CYP2C9.1 and
that of the 7-hydroxywarfarin were made using OriginPro 7.5
(OriginLab, Northampton, MA, USA) with linear fitting. Prism
4.0 software (GraphPad, San Diego, CA, USA) was used to
calculate kinetic parameters of different CYP2C9 variants toward
S-warfarin 7-hydroxylation with nonlinear regression analysis
of a Michaelis-Menten equation. Statistical comparisons were
performed using IBM SPSS Statistics 14.0 (IBM, Armonk, NY,
USA) with Dunnett t-tests, which treat one group as a control,
and compare all other groups against it. It was considered to be
statistically significant when the value of P < 0.05.
RESULTS
The wild type CYP2C9 and these five allelic variants identified
in our previous study were expressed in COS-7 cells. Apoprotein
levels of these recombinant CYP2C9s were measured by
immunoblotting with baculovirus-expressed CYP2C9 as
the standard. As shown in Figure 1A, all of them were
immunodetectable with the rabbit-produced anti-CYP2C9
antibody. Using brands of baculovirus-expressed CYP2C9.1
with known quantities as the standard curve, the CYP2C9
apoprotein contents in COS-7 cell-generated microsomes could
be quantified (Figure 1B). The expression level of CYP2C9.1
was 27.75 ± 2.73 (mean ± S.D.) pmol/mg microsomal protein.
Statistical comparisons (Dunnett t-tests) between CYP2C9.1 (the
wild type of CYP2C9) and other CYP2C9 allelic variants showed
that the expression levels of CYP2C9.3, CYP2C9.8, CYP2C9.11
had no statistical difference (P = 0.05) from that of CYP2C9.1.
The expression level of CYP2C9.2 was the lowest, with an
amount of 11.24 ± 0.16 (mean ± SD) pmol/mg microsomal
protein (40.5% of CYP2C9.1 expression level, P < 0.001).
FIGURE 1 | Detection of CYP2C9 proteins by western-blot analysis (A)
and the relative expression level of CYP2C9 proteins expressed in
COS-7 cells (B). Recombinant CYP2C9s were recognized by
rabbit-produced anti-CYP2C9 antibody, and experiments were conducted in
triplicate independently.
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CYP2C9.31 exhibited moderate decreased expression level
(56.6% of that of CYP2C9.1, P < 0.05).
In vitro catalytic activity of these COS-7 cell-expressed
CYP2C9 toward S-warfarin 7-hydroxylation was evaluated
with experiments conducted in triplicate independently. As
shown in Figure 2, all recombinant CYP2C9s presented typical
Michaelis-Menten kinetic profiles. Kinetic parameters (Km,
Vmax and CLint) of them were summarized in Table 1, with
data shown in the form of mean ± S.D. The estimated
kinetic parameters Km, Vmax and Clint of COS-7 cell-expressed
CYP2C9.1 (wild type) toward S-warfarin 7-hydroxylation were
2.92µM, 1.80 pmol/min/pmol CYP2C9 and 0.61µL/min/pmol
CYP2C9, respectively. Relative to the wild type CYP2C9,
recombinant CYP2C9.3 and CYP2C9.11 exhibited significantly
higher Km values (1.64-fold and 1.52-fold, respectively; P <
0.001). Besides, all variants showed significantly lower Vmax(P
< 0.001). Among them, the Vmax value for CYP2C9.3 is the
lowest, which was only 15% of the wild type. Accordingly,
all recombinant variants exhibited significantly decreased Clint
values (P < 0.001), among which Clint values for CYP2C9.3 and
CYP2C9.11 decreased the most (8.2% and 9.8% of CYP2C9.1,
respectively).
FIGURE 2 | Kinetics of S-warfarin 7-hydroxylation by COS-7
cell-expressed CYP2C9.1, CYP2C9.2, CYP2C9.3, CYP2C9.8,
CYP2C9.11 and CYP2C9.31. Every point represents the mean of three
independent experiments.
DISCUSSION
Variability in CYP2C9 activity is an important contributor to
interindividual drug response variations, especially for drugs
with a narrow therapeutic index, such asWarfarin. In the present
study, we focused on five CYP2C9 alleles (CYP2C9∗2,CYP2C9∗3,
CYP2C9∗8, CYP2C9∗11, and CYP2C9∗31) identified in Chinese
Han population, expressed all of them as well as the wild type
enzyme in COS-7 cells, and characterized their catalytic activity
with S-warfarin as the representative substrate. Apoprotein levels
of these recombinant CYP2C9s were measured by immunoblot
analysis, because accurate quantification of their holoprotein
levels by CO difference spectroscopy was reported to be difficult
due to low levels of expression (Hiratsuka, 2012). Even though
immunoblot analysis might overestimate the P450 levels of these
CYP2C9 levels, resulting in the overestimation ofClint values, this
method has gained its popularity in estimating the apoprotein
levels of CTP2C9 as well asmany other CYPs, including CYP2D6,
CYP2B6, and CYP2E1, especially when mammalian cells were
used as the expression system (Marcucci et al., 2002; Hanioka
et al., 2003; Watanabe et al., 2010).
Catalytic activity of these 5 CYP2C9 variants toward S-
warfarin 7-hydroxylation was measured with triple independent
experiments. Compared with the wide type, all allelic variants
exhibited impaired enzymatic activity. Among them, in vitro
functional characterization of CYP2C9∗2 and CYP2C9∗3 have
been reported most extensively. In most of the previous studies,
both CYP2C9∗2 and CYP2C9∗3 were associated with impaired
catalytic activities, such as lower Vmax and higher intrinsic
clearance values (Rettie et al., 1994), higher Km and lower
Clint values (Guo et al., 2005), toward a variety of CYP2C9
substrates, relative to the wild type. In our present study,
both recombinant CYP2C9.2 and CYP2C9.3 exhibited impaired
catalytic activity toward S-warfarin 7-hydroxylation (24.6% and
8.2% of Clint ratio, respectively), which were similar to values
reported previously. The mechanisms involved in the decreased
catalytic activities of CYP2C9.2 and CP2C9.3 may be related to
the enzyme conformational changes. Wei et al. (2007) reported
that the conversion of enzyme to the high spin state was similar
in CYP2C9.1 and CYP2C9.2, but lower in CYP2C9.3; and neither
altered substrate binding nor altered interaction with reductase
TABLE 1 | In vitro kinetic parameters for S-warfarin 7-hydroxylation by COS-7 cell-expressed CYP2C9.1, CYP2C9.2, CYP2C9.3, CYP2C9.8, CYP2C9.11,
and CYP2C9.31.
Variant Nucleotide transitions Kma Vmaxa CLinta
µM pmol/min/pmol CYP2C9 µL/min/pmol CYP2C9
CYP2C9.1 Wild type 2.92± 0.25 1.80± 0.040 0.61± 0.039
CYP2C9.2 430 C>T 3.13± 0.23 0.48± 0.005***b 0.15± 0.010***b
CYP2C9.3 1075 A>C 4.78± 0.10***b 0.27± 0.001***b 0.05± 0.000***b
CYP2C9.8 449 G>A 2.43± 0.24 0.70± 0.014***b 0.28± 0.023***b
CYP2C9.11 1003 C>T 4.44± 0.04***b 0.31± 0.001***b 0.06± 0.000***b
CYP2C9.31 980 T>C 2.66± 0.14 0.32± 0.002***b 0.12± 0.005***b
aEach value represents the mean ± SD of three independent experiments.
b***P < 0.001 vs. wild type with a Dunnett t-test.
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appeared to be involved in the reduced catalysis. Besides, the
R144C substation caused by CYP2C9∗2 was suggested to affect
the interaction between CYP2C9 enzyme and the P450 reductase,
while the I359L substitution caused by CYP2C9∗3 might affect
the substrate recognition (Gotoh, 1992; Crespi and Miller, 1997).
The CYP2C9∗8 (449G>A) allele resulted in an R150H
substitution with a frequency of 1.8% in ChineseHan populations
(Xiong et al., 2011). In the present study, the COS-7 cell-
expressed CYP2C9.8 exhibited a reduced value of intrinsic
clearance (45.9% of the wild type) and a significantly lower
Vmax value (38.9% of the wild type) toward S-warfarin 7-
hydroxylation. Our results are in accordance with the previously
reported studies both in vivo and in vitro. Recently, Liu et al.
(2012) reported that patients carrying the CYP2C9∗8 allele
exhibited a 30% reduction in the unbound oral clearance of S-
warfarin than CYP2C9∗1 homozygotes; and the in vitro intrinsic
clearance of cDNA-expressed CYP2C9.8 toward S-warfarin
metabolism was also 30% lower as compared with the wild type
protein. Along with previous studies, our findings might provide
explanations for the lower warfarin dose requirements in patients
with the CYP2C9∗8 allele.
CYP2C9∗11 is a C1003T mutation in exon 7, leading to
an Arg335Trp substitution. It has been detected in Caucasians,
Africans as well as Asians (Allabi et al., 2005; Xiong et al.,
2011). The Arg335 is located in the turn between the J and J’
helices and forms a hydrogen-bonding ion pair with Asp341
from the J’ helix, which plays an important role in the secondary
structure stabilization. Blaisdell et al. (2004) Thus the Arg335Trp
substitution will abolish this interaction and alter the substrate
affinity. In our study, the COS-7 cell-expressed CYP2C9.11
showed a 1.5-fold higher Km value, significantly lower Vmax
and reduced intrinsic clearance (P < 0.001) than the wild
type. In the most recent report of Niinuma et al. (2014),
CYP2C9.11 exhibited significantly lower catalytic activity for
40µM S-warfarin than wild-type CYP2C9.1, although they did
not determine the Michaelis–Menten kinetics for CYP2C9.11.
Besides, Blaisdell et al. (2004) reported that the E. coli-expressed
CYP2C9.11 exhibited a three-fold increase in the Km and more
than two-fold decrease in the intrinsic clearance for tolbutamide;
and Allabi et al. (2005) reported that, in black population, there
was a marked reduction of CYP2C9 activity in subjects carrying
at least one CYP2C9∗11 allele. Our findings are also in line with
both in vitro and in vivo studies previously reported.
The CYP2C9∗31 allele was detected in Africans firstly, and
was predicted to have a possible functional damage (Matimba
et al., 2009). Although there have been no reports about in
vivo functional assessment of CYP2C9∗31 by now, Niinuma
et al. (2014) reported that the COS-7 cell-expressed CYP2C9.31
exhibited significantly decreased enzyme activity, when using
S-warfarin as the representative substrate, without determining
the kinetic parameters (Km, Vmax and Clint). Dai et al. (2013)
reported that the insect cell-expressed CYP2C9.31 showed
significantly reduced intrinsic clearance value (34.4% of the
wild type). Ji et al. (2015) reported that the insect cell-
expressed CYP2C9.31 exhibited significantly lower intrinsic
clearance value than CYP2C9∗1 toward fluoxetine. However,
in contrast to their previous in vitro metabolic assessments
on tolbutamide, losartan and glimepiride, CYP2C9.31 exhibited
substrate inhibition trend toward fluoxetine, which did not follow
the Michaelis–Menten kinetics. In our findings, the estimated
Km, Vmax and Clint values for CYP2C9.31 toward S-warfarin
7-hydroxylation were 2.66µM (not significantly different from
CYP2C9.1), 0.32 pmol/min/pmol CYP2C9 (17.8% of the wild
type, P < 0.001) and 0.12µL/min/pmol (19.7% of the wild
type, P < 0.001), respectively. All these findings suggested that
this allele was associated with significantly decreased enzymatic
activity and patients carrying this allele should be given different
drug treatments from patients carrying the wild type CYP2C9.
In conclusion, we expressed these five CYP2C9 allelic variants
as well as the wild type CYP2C9 in COS-7 cells. The Michaelis–
Menten kinetics for all these recombinant CYP2C9s were
determined with S-warfarin as the representative substrate. All
allelic variants exhibited significantly decreased catalytic activity.
In the present study, we have not given the results of the
combined CYP2C9 variants for their lowminor allele frequencies
(MAF) based on our previous study (Xiong et al., 2011). However,
it is still possible that haplotypes may give different results.
These findings should be useful for predicting the phenotype
profiles of CYP2C9 in Chinese Han population, which could
contribute to optimizing dosage recommendations, maximizing
the efficacy and minimizing the adverse responses of drug
treatment, particularly for Chinese Han population.
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